Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1999 Oct;67(4):451–456. doi: 10.1136/jnnp.67.4.451

Randomised, double blind, placebo controlled study of interferon β-1a in relapsing-remitting multiple sclerosis analysed by area under disability/time curves

C Liu 1, L Blumhardt 1
PMCID: PMC1736573  PMID: 10486390

Abstract

OBJECTIVES—The commonly employed outcome measures on disability and relapse rates in treatment trials of relapsing-remitting multiple sclerosis have well demonstrated sensitivity to treatment effects, but their clinical interpretation is problematic. An alternative method of analysis, which is more clinically meaningful and statistically appropriate to a condition with a fluctuating disease course, uses the summary measure statistic "area under the disability/time curve (AUC)", to estimate each patient's total in trial morbidity experience.
METHODS—The AUC technique was applied in an intention to treat analysis of serial disability data derived from the expanded disability status scale (EDSS), the Scripps neurologic rating scale (SNRS), and the ambulation index (AI), collected during a double blind, randomised, placebo controlled, phase III trial of subcutaneous interferon β-1a (INFβ-1a) in relapsing-remitting multiple sclerosis (PRISMS Study). The results were compared with the often quoted "conventional" end point of mean change in rating scores from baseline to trial completion. Analyses were also carried out on subgroups with entry EDSS stratified above and below 3.5.
RESULTS—EDSS data analysed by AUC normalised to baseline scores disclosed that both doses of IFNβ-1a (22 or 44 µg) were superior to placebo (p= 0.008 and 0.013, respectively). In addition, the high dose (44 µg) was more beneficial than placebo using SNRS (p= 0.038) and AI data (p= 0.039). AUC analysis of SNRS scores also showed that for patients with baseline EDSS>3.5, the 44 µg (but not the 22 µg) dose was more advantageous than placebo (p=0.028).
CONCLUSIONS—Summary measure analysis using the AUC of serial disability/time plots, confirms and extends the results of conventional end point analysis of disability from the PRISMS Study data. AUC evaluations show that high dose INFβ-1a (44 µg three times weekly) was beneficial on all of the clinical rating scale scores used in this study. This method provides a statistically powerful and clinically meaningful assessment of treatment effects on in trial disability in patients with multiple sclerosis with fluctuating and highly heterogeneous disease courses.



Full Text

The Full Text of this article is available as a PDF (115.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALEXANDER L., BERKELEY A. W., ALEXANDER A. M. Prognosis and treatment of multiple sclerosis-quantitative nosometric study. J Am Med Assoc. 1958 Apr 19;166(16):1943–1949. doi: 10.1001/jama.1958.02990160001001. [DOI] [PubMed] [Google Scholar]
  2. Confavreux C., Aimard G., Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain. 1980 Jun;103(2):281–300. doi: 10.1093/brain/103.2.281. [DOI] [PubMed] [Google Scholar]
  3. Fazekas F., Deisenhammer F., Strasser-Fuchs S., Nahler G., Mamoli B. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997 Mar 1;349(9052):589–593. doi: 10.1016/s0140-6736(96)09377-4. [DOI] [PubMed] [Google Scholar]
  4. Francis D. A., Bain P., Swan A. V., Hughes R. A. An assessment of disability rating scales used in multiple sclerosis. Arch Neurol. 1991 Mar;48(3):299–301. doi: 10.1001/archneur.1991.00530150067020. [DOI] [PubMed] [Google Scholar]
  5. Goodkin D. E., Cookfair D., Wende K., Bourdette D., Pullicino P., Scherokman B., Whitham R. Inter- and intrarater scoring agreement using grades 1.0 to 3.5 of the Kurtzke Expanded Disability Status Scale (EDSS). Multiple Sclerosis Collaborative Research Group. Neurology. 1992 Apr;42(4):859–863. doi: 10.1212/wnl.42.4.859. [DOI] [PubMed] [Google Scholar]
  6. Goodkin D. E., Hertsgaard D., Seminary J. Upper extremity function in multiple sclerosis: improving assessment sensitivity with box-and-block and nine-hole peg tests. Arch Phys Med Rehabil. 1988 Oct;69(10):850–854. [PubMed] [Google Scholar]
  7. Gronwall D., Wrightson P. Delayed recovery of intellectual function after minor head injury. Lancet. 1974 Sep 14;2(7881):605–609. doi: 10.1016/s0140-6736(74)91939-4. [DOI] [PubMed] [Google Scholar]
  8. Hauser S. L., Dawson D. M., Lehrich J. R., Beal M. F., Kevy S. V., Propper R. D., Mills J. A., Weiner H. L. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med. 1983 Jan 27;308(4):173–180. doi: 10.1056/NEJM198301273080401. [DOI] [PubMed] [Google Scholar]
  9. Hughes R. A., Sharrack B. More immunotherapy for multiple sclerosis. J Neurol Neurosurg Psychiatry. 1996 Sep;61(3):239–241. doi: 10.1136/jnnp.61.3.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  11. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 Jul;45(7):1268–1276. doi: 10.1212/wnl.45.7.1268. [DOI] [PubMed] [Google Scholar]
  12. Koziol J. A., Frutos A., Sipe J. C., Romine J. S., Beutler E. A comparison of two neurologic scoring instruments for multiple sclerosis. J Neurol. 1996 Mar;243(3):209–213. doi: 10.1007/BF00868516. [DOI] [PubMed] [Google Scholar]
  13. Kurtzke J. F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983 Nov;33(11):1444–1452. doi: 10.1212/wnl.33.11.1444. [DOI] [PubMed] [Google Scholar]
  14. Liu C., Blumhardt L. D. Assessing relapses in treatment trials of relapsing and remitting multiple sclerosis: can we do better? Mult Scler. 1999 Feb;5(1):22–28. doi: 10.1177/135245859900500105. [DOI] [PubMed] [Google Scholar]
  15. Liu C., Li Wan Po A., Blumhardt L. D. "Summary measure" statistic for assessing the outcome of treatment trials in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 1998 Jun;64(6):726–729. doi: 10.1136/jnnp.64.6.726. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Matthews J. N., Altman D. G., Campbell M. J., Royston P. Analysis of serial measurements in medical research. BMJ. 1990 Jan 27;300(6719):230–235. doi: 10.1136/bmj.300.6719.230. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., Lublin F., Miller A., Petkau J., Rao S. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep;40(3):469–479. doi: 10.1002/ana.410400321. [DOI] [PubMed] [Google Scholar]
  18. Rudick R., Antel J., Confavreux C., Cutter G., Ellison G., Fischer J., Lublin F., Miller A., Petkau J., Rao S. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep;42(3):379–382. doi: 10.1002/ana.410420318. [DOI] [PubMed] [Google Scholar]
  19. Runmarker B., Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain. 1993 Feb;116(Pt 1):117–134. doi: 10.1093/brain/116.1.117. [DOI] [PubMed] [Google Scholar]
  20. Schwid S. R., Goodman A. D., Mattson D. H., Mihai C., Donohoe K. M., Petrie M. D., Scheid E. A., Dudman J. T., McDermott M. P. The measurement of ambulatory impairment in multiple sclerosis. Neurology. 1997 Nov;49(5):1419–1424. doi: 10.1212/wnl.49.5.1419. [DOI] [PubMed] [Google Scholar]
  21. Sharrack B., Hughes R. A. Clinical scales for multiple sclerosis. J Neurol Sci. 1996 Jan;135(1):1–9. doi: 10.1016/0022-510x(95)00261-y. [DOI] [PubMed] [Google Scholar]
  22. Sipe J. C., Knobler R. L., Braheny S. L., Rice G. P., Panitch H. S., Oldstone M. B. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology. 1984 Oct;34(10):1368–1372. doi: 10.1212/wnl.34.10.1368. [DOI] [PubMed] [Google Scholar]
  23. Weinshenker B. G., Bass B., Rice G. P., Noseworthy J., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain. 1989 Dec;112(Pt 6):1419–1428. doi: 10.1093/brain/112.6.1419. [DOI] [PubMed] [Google Scholar]
  24. Weinshenker B. G., Rice G. P., Noseworthy J. H., Carriere W., Baskerville J., Ebers G. C. The natural history of multiple sclerosis: a geographically based study. 4. Applications to planning and interpretation of clinical therapeutic trials. Brain. 1991 Apr;114(Pt 2):1057–1067. doi: 10.1093/brain/114.2.1057. [DOI] [PubMed] [Google Scholar]
  25. Whitaker J. N., McFarland H. F., Rudge P., Reingold S. C. Outcomes assessment in multiple sclerosis clinical trials: a critical analysis. Mult Scler. 1995 Apr;1(1):37–47. doi: 10.1177/135245859500100107. [DOI] [PubMed] [Google Scholar]
  26. Willoughby E. W., Paty D. W. Scales for rating impairment in multiple sclerosis: a critique. Neurology. 1988 Nov;38(11):1793–1798. doi: 10.1212/wnl.38.11.1793. [DOI] [PubMed] [Google Scholar]
  27. Wingerchuk D. M., Noseworthy J. H., Weinshenker B. G. Clinical outcome measures and rating scales in multiple sclerosis trials. Mayo Clin Proc. 1997 Nov;72(11):1070–1079. doi: 10.4065/72.11.1070. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES